Ashish Saxena, MD, PhD


Analyzing Outcomes of Immune Checkpoint Blockade Plus Chemo in SCLC

Ashish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.

Rebecca Dent, MD


Addressing the Mechanism of Action for the AKT Pathway in TNBC

Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.

Edwin Choy, MD


Adjuvant Therapy for GIST

Edwin Choy, MD, discusses adjuvant treatments for patients with gastrointestinal stromal tumors.

John E. Sylvester, MD


Early Detection & the Right Treatment Critical for Prostate Cancer

John E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.

Scott Tagawa, MD, MS, FACP


Future Directions in Prostate Cancer and Clinical Pearls for Clinicians

Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.

Emma Searle, PhD


Addressing Dosing Methods With Teclistamab in Multiple Myeloma

Emma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.

Brian M. Slomovitz, MD


Looking Toward the Future of Endometrial Cancer Management

Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.

Jamie E. Chaft, MD


Durvalumab After Chemotherapy Helps Manage Toxicities in NSCLC Treatment

Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.

Rebecca Silbermann, MD, MMS


Importance of Patient-Reported Outcomes in the GRIFFIN Study

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

Shubham Pant, MD


Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic Cancer

Shubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.

Lipika Goyal, MD


Sequencing Therapies in the First and Second Line for Patients With HCC

Lipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.

Kruti Patel, DO


Advances in CAR T-Cell Therapy in Hematologic Malignancies

Kruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.

Matthew S. McKinney, MD


Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCL

Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.

Samuel J. Klempner, MD


Zolbetuximab Plus mFOLFOX for CLDN18.2+/HER2- Advanced Gastric/GEJ Cancers

Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.

Ronald S. Go, MD


Recommendations for Diagnosing and Treating Rare Histiocytic Neoplasms

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Valencia Thomas, MD


Thomas Discusses Non-Melanoma Skin Cancers

Valencia D. Thomas, MD, MHCM, discusses the current landscape for patients with non-melanoma skin cancers.

Thomas G. Martin, MD


Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma

Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.

Richard L. Wahl, MD


Lu 177 Vipivotide Tetraxetan Approved for PSMA-Positive mCRPC

Richard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Kavitha Ramchandran, MD


Palliative Care Plays Important Role in Advanced Cancers

Kavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.

Melina E. Marmarelis, MD


Ongoing Trials Investigate Amivantamab Combinations for EGFR+ NSCLC

Melina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.

Hannah Slater


Bemcentinib/Pembrolizumab Shows Clinical Activity, Tolerability in Advanced NSCLC

Patients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.

Carlos R. Bachier, MD


Evaluating the Feasibility of Liso-cel Administration in the Outpatient Setting

Carlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.

Nitika Sharma, MD
Nitika Sharma, MD


Recent Advances in Esophageal Cancers Go Beyond a One-Size-Fits-All Approach

Nitika Sharma, MD, explores developments in the esophageal cancer landscape for Esophageal Cancer Awareness Month.

Erminia Massarelli, MD


Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Stephen J. Schuster, MD


Exploring the Use of Tisagenlecleucel for Patients With Lymphoma

Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.

Susana Banerjee, MBBS, PhD


Implications of the MEDIOLA Trial Results in Relapsed Ovarian Cancer

Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.

Tim Smith


Relationship Between Plaque Psoriasis and Cancer Risk Identified

In a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.

Nazli Dizman, MD


Analyzing the Role of Gut Microbiome in Renal Cell Carcinoma

Nazli Dizman, MD, internal medicine resident at Yale Department of Internal Medicine, discusses the role of the gut microbiome in cancers like renal cell carcinoma.

Lucy Langer, MD


Genetic Testing Empowers Better Cancer Care, Prevention, and Early Detection

Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.